News
- Curve Therapeutics Co-Founder and CSO Professor Ali Tavassoli awarded the Royal Society of Chemistry’s Interdisciplinary Prize 25 June 2025
- From big pharma to biotech; reflections on the UK life sciences industry amid British Science Week 14 March 2025
- How Curve’s Proprietary Microcycle® Discovery Platform is Reinventing Drug Discovery 18 February 2025
- 2024 a transformational year of progress: A note from the CEO 20 December 2024
- Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer 9 October 2024
- Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board 2 October 2024
- Curve Therapeutics strengthens Leadership Team with appointment of experienced biotech executive Simon Jones 9 July 2024
- Research published in Journal of the American Chemical Society highlights potential of HIF Inhibition as a therapeutic approach for cancers 26 March 2024
- Curve Therapeutics April 2024 Conference Attendance 21 March 2024
- Curve Therapeutics raises £40.5 million to turbocharge discovery platform and advance breakthrough pipeline 27 February 2024
- Curve Therapeutics appoints Dr Sally Price as Vice President of Biology 18 September 2023
- Curve Therapeutics Expands Leadership Team and Scientific Advisory Board: Dr Monika Ermann appointed Vice President Drug Discovery to advance Curve’s therapeutic programmes directed at challenging cancer targets 2 May 2023
- Curve CSO featured in the “Careers in Drug Discovery” podcast 18 January 2023
- Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform 16 February 2022
- Curve Therapeutics Participates in Parliamentary Meetings 8 September 2021
- Curve Therapeutics Announces Grant of US Patent 31 March 2021
- Curve Therapeutics Announces Investment from co-lead Epidarex Capital 31 July 2020
- Curve Therapeutics Announces Seed Investment from Advent Life Sciences 27 June 2019
